- Why Medical Device Clinical Trial Cost Varies So Much
- The US Baseline: What a First-in-Human Trial Costs Domestically
- Latin America: Where the Cost Advantage Actually Lives
- What Drives Cost Differences at the Program Level
- How bioaccess® Structures the Cost Comparison
- A Practical Cost Framework for Founders
- FAQs
- Make the Cost Comparison Before You Commit
If you're a MedTech or biopharma founder with $1M–$5M earmarked for your first-in-human milestone, where you run the trial matters as much as how you design it. The same protocol can carry dramatically different price tags depending on geography — and the gap isn't just about per-patient rates. It's about regulatory timelines, site activation delays, and the compounding cost of time when you're burning runway.
This article breaks down the real cost drivers behind a first-in-human medical device trial in the United States versus Latin America, so you can make a more informed decision before issuing an RFP.
Why Medical Device Clinical Trial Cost Varies So Much
A first-in-human trial isn't a single line item. Total cost is the sum of several distinct cost centers, and each one behaves differently depending on where you run the study.
The main buckets are:
- Regulatory and ethics approval fees and timelines
- Site activation costs (qualification, contracting, training)
- Per-subject costs (screening, procedures, follow-up, stipends)
- CRO management fees (project management, monitoring, data management)
- Clinical study report and submission preparation
- Overhead from delays (extended site management, sponsor team time, investor timeline pressure)
That last item is the one founders most consistently underestimate. A six-month regulatory delay in the US doesn't just cost you six months of CRO fees. It costs you six months of burn rate, a potentially missed funding milestone, and the compounding risk of a competitor reaching clinical data first.
The US Baseline: What a First-in-Human Trial Costs Domestically
Running a first-in-human medical device study in the United States under an IDE means navigating FDA review, IRB approval, and site contracting at academic medical centers or specialized Phase I clinics. None of those steps move quickly.
Regulatory and IRB timelines
FDA IDE review alone takes 30 days for a non-significant risk determination and up to 180 days for a significant risk device. IRB review at a single institution typically adds another 30–90 days. Multi-site studies multiply that burden. In practice, US sponsors routinely spend 6–12 months in the pre-enrollment phase before a single patient is screened.
Per-subject costs in North America
Published market data puts North American Phase I per-subject costs between $15,000 and $50,000-plus, depending on device complexity, procedure intensity, and follow-up duration. For a 15-subject feasibility study, that's $225,000 to $750,000 in subject-related costs alone — before CRO fees, site management, or data work.
CRO and operational overhead
Large US CROs typically scope FIH engagements across multiple internal teams: regulatory affairs, clinical operations, data management, and medical writing each operate as separate cost centers. Sponsors coordinate across those silos, which adds both cost and timeline risk. A full-service FIH engagement through a major US CRO can run well into seven figures for a medical device study with meaningful complexity.
The timeline tax
At a typical seed-to-Series-B burn rate, 18–24 months of US trial execution represents a material portion of a funding round. If your Series A closes in Q3 and your board expects first human data before your Series B roadshow, a 24-month US timeline doesn't fit. That gap is where Latin America stops being operationally interesting and starts being financially necessary.
Latin America: Where the Cost Advantage Actually Lives
The cost advantage of running a first-in-human trial in Latin America is real — but it's more nuanced than a simple per-patient discount. The advantage compounds across three separate dimensions.
Regulatory speed in specific jurisdictions
Not all Latin American countries offer the same regulatory environment. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30–90 days. That's not a general claim about the region — it's specific to those four jurisdictions and the regulatory bodies that govern them: MINSA/CNBI in Panama, ISP/MINSAL in Chile, and SRS/CNEIS in El Salvador.
Compare that to 6–12 months in the US or EU. For a founder on a 12–18 month runway, that difference can determine whether you hit a milestone or miss it.
Other Latin American markets — Argentina, Brazil, Colombia, Mexico, Peru — carry longer regulatory timelines that narrow or eliminate this advantage. Jurisdiction selection is not interchangeable.
Site activation and per-subject economics
Pre-qualified sites in Panama, El Salvador, Chile, and the Dominican Republic operate with lower overhead than US academic medical centers. Site activation timelines are shorter, contracting is more straightforward, and per-subject costs reflect a different economic baseline — producing meaningfully lower cost per enrolled subject compared to North American Phase I clinic rates.
This doesn't mean lower quality. Sites operating under ICH-GCP standards and ISO 14155 protocol architecture produce data that meets FDA requirements for foreign clinical data acceptance under 21 CFR 812.28. The cost savings don't come at the expense of regulatory usability.
The compounding value of 12 months vs. 24 months
If a US trial takes 18–24 months and a structured Latin America program delivers a submission-ready evidence package within 12 months, the cost comparison isn't just about per-patient rates. It's about total capital consumed during the trial period.
A 12-month program means:
- Fewer months of CRO management fees
- Less sponsor team time allocated to trial oversight
- A faster path to the data package that unlocks the next funding round
- Lower risk of timeline-driven dilution or bridge financing
For a startup with $2M–$3M allocated to the FIH milestone, the difference between a 12-month and a 24-month program can represent 30–50% of total trial spend — before you account for per-subject cost differences.
What Drives Cost Differences at the Program Level
Beyond geography, the structure of your CRO engagement has a significant impact on total cost. Two variables matter most.
Single-vendor vs. multi-vendor coordination
When a sponsor coordinates across separate regulatory, clinical operations, data management, and medical writing vendors, every handoff creates cost and delay. Scope gaps between vendors generate change orders. Misaligned timelines create idle time that still gets billed.
A single-vendor engagement — where one accountable team manages all workstreams from protocol development through final clinical study report — eliminates most of that friction. The savings from reduced coordination overhead are real, even if they're harder to quantify on a line-item basis than per-subject rates.
Packaged vs. bespoke scoping
Large CROs typically scope FIH studies from scratch, which means weeks of back-and-forth on protocol, budget, and timeline before a contract is signed. A structured program with defined workstreams and a fixed timeline framework reduces pre-contract friction and gives sponsors a clearer picture of total program cost before they commit.
How bioaccess® Structures the Cost Comparison
bioaccess® operates specifically in Panama, El Salvador, Chile, and the Dominican Republic — the four jurisdictions where 30–90 day regulatory approvals are achievable. Its FIH-12™ program is a nine-workstream engagement that takes a sponsor from protocol development to a submission-ready evidence package within 12 months, managed by one accountable team.
That structure addresses both the geographic cost advantage and the coordination overhead problem at once. Sponsors don't manage separate regulatory, clinical, and data vendors. One team handles FDA strategy alignment, protocol development, site activation, patient enrollment, data management, and final clinical study report delivery — start to finish.
The program is built specifically for seed-to-Series-B startups whose capital cycles don't accommodate 18–24 month US timelines. All data is structured for FDA acceptance under 21 CFR 812.28, so the evidence package produced in Latin America is directly usable for US IDE and IND submissions.
Pricing is not publicly disclosed. bioaccess® offers a FIH Launch Planner — a six-question tool that generates a preliminary country route, timeline range, and evidence package estimate based on your device class. Intake is limited to 8 new programs per quarter.
A Practical Cost Framework for Founders
If you're building a budget for your FIH milestone, here's how the two paths compare:
US-based FIH trial (IDE pathway):
- Regulatory and IRB timeline: 6–12 months pre-enrollment
- Per-subject costs: $15,000–$50,000-plus (published North American market range)
- CRO management: typically scoped across multiple internal teams
- Total program timeline: 18–24 months common for medical device FIH studies
- Data usability: directly FDA-applicable
Latin America FIH trial (bioaccess® FIH-12™, specific jurisdictions):
- Regulatory and ethics timeline: 30–90 days in Panama, El Salvador, Chile, Dominican Republic
- Per-subject costs: lower than North American baseline given site economics
- CRO management: single-vendor, nine-workstream accountability
- Total program timeline: 12 months under the FIH-12™ structured program
- Data usability: FDA-accepted under 21 CFR 812.28
The decision isn't purely about cost per subject. It's about total capital consumed, how well the timeline fits your funding cycle, and the risk profile of each path.
FAQs
Is data from a Latin American first-in-human trial accepted by the FDA?
Yes, when structured correctly. The FDA accepts foreign clinical data under 21 CFR 812.28, provided the study meets applicable standards. bioaccess® structures all FIH data under ICH-GCP and ISO 14155 protocol architecture specifically to meet this requirement, making the evidence package usable for US IDE and IND submissions.
Why are regulatory approvals faster in Panama, El Salvador, Chile, and the Dominican Republic than in the US?
These jurisdictions have streamlined ethics and regulatory review processes that operate on 30–90 day timelines. This is specific to these four countries and the regulatory bodies governing them — MINSA/CNBI in Panama, ISP/MINSAL in Chile, and SRS/CNEIS in El Salvador. It does not apply to Latin America broadly; markets like Brazil or Argentina carry longer timelines.
What is the published per-subject cost range for North American Phase I trials?
Published market data cites North American Phase I per-subject costs between $15,000 and $50,000-plus, depending on device complexity, procedure intensity, and follow-up requirements. This is a market range, not a bioaccess® figure.
Does running a trial in Latin America mean lower data quality?
No. Sites operating under ICH-GCP standards and ISO 14155 protocol architecture meet the same quality standards required for FDA submission. The cost difference reflects site economics — not a reduction in data integrity or regulatory usability.
What is the FIH-12™ program and how does it affect total trial cost?
FIH-12™ is bioaccess®'s structured nine-workstream program that delivers a submission-ready evidence package within 12 months. Because one team manages all workstreams — from FDA strategy alignment through final clinical study report — sponsors avoid the coordination overhead and change order risk that comes with multi-vendor engagements. That structure affects total cost as much as per-subject rates do.
How does the 12-month timeline affect startup fundraising?
Most seed-to-Series-B MedTech founders need first human data before their next funding round closes. A 12-month program fits within a typical Series A-to-Series-B window. An 18–24 month US timeline often doesn't, which forces founders into bridge financing or timeline compression — both of which carry their own costs and risks.
How do I get a cost estimate for a Latin American FIH trial?
bioaccess® does not publish pricing publicly. The FIH Launch Planner on the website generates a preliminary country route, timeline range, and evidence package estimate based on six questions about your device class and program stage. Intake is limited to 8 new programs per quarter.
Make the Cost Comparison Before You Commit
The cost of a first-in-human trial isn't fixed by your protocol. It's shaped by where you run it, how your CRO is structured, and how well the program timeline fits your capital cycle.
If you're 12–24 months from needing first human data and your funding window doesn't accommodate a 24-month US timeline, the Latin America comparison is worth running in detail — not as a fallback, but as a primary strategic option.
Use the FIH Launch Planner at bioaccessla.com to get a preliminary country route and timeline estimate for your specific device class.
Leave a Reply